Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Total Liabilities (2019 - 2025)

Silo Pharma's Total Liabilities history spans 7 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 22.9% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 22.9%, while the annual FY2024 figure was $2.4 million, 51.51% up from the prior year.
  • Total Liabilities for Q3 2025 was $1.4 million at Silo Pharma, down from $1.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.4 million in Q4 2024 and bottomed at $1.2 million in Q2 2022.
  • The 5-year median for Total Liabilities is $1.5 million (2023), against an average of $1.6 million.
  • The largest annual shift saw Total Liabilities skyrocketed 1250.23% in 2021 before it dropped 22.9% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $1.4 million in 2021, then fell by 8.81% to $1.3 million in 2022, then rose by 20.52% to $1.6 million in 2023, then skyrocketed by 51.51% to $2.4 million in 2024, then plummeted by 42.13% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Total Liabilities are $1.4 million (Q3 2025), $1.7 million (Q2 2025), and $1.9 million (Q1 2025).